Accelerating decisions in immunotherapy with predictive single-cell response

Isoplexis helps researchers target the right therapies early to the highest-urgency cancer patients.

Like Comment
Page of
Go to the profile of Isoplexis


IsoPlexis is a life sciences company committed to advancing precision medicine in the fight against cancer, autoimmune and infectious diseases. The IsoPlexis single cell detection platform isolates single immune cells and analyzes their full functional response to assess the effectiveness of therapeutics and to predict patient clinical response. The newly introduced Isolight® Next Generation Single Cell Analysis system is a versatile precision engineering platform designed to understand and characterize differences among single cells, mapping thousands of cells per sample, to reveal full functional profiles and polyfunctionality among cell subsets to determine patient response and product quality.

No comments yet.